Moderna co-founder and board chairman Noubar Afeyan discusses the phase three success of the Moderna-Merck cancer vaccine trial and explains how the vaccine targets unique mutations to help prevent melanoma recurrence on ‘The Claman Countdown.’ #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #moderna #merck #cancer #vaccine #health #medicine #medical #melanoma #science #research #trial #biotech #technology #treatment #breakthrough #healthcare #innovation
Moderna CEO Stéphane Bancel joins ‘Mornings with Maria’ to discuss the company's landmark cancer vaccine partnership with Merck. Bancel details the promising Phase 3 melanoma trial results and outlines Moderna's latest financial growth outlook. #foxbusiness #morningswithmaria 0:03 – Moderna and Merck’s Personalized Cancer Vaccine Breakthrough 1:18 – Moderna Targets FDA Approval for Next Year 2:20 – Expanding mRNA Cancer Treatment Beyond Melanoma 5:21 – Moderna’s mRNA Push: Rare Diseases and a New Flu Vaccine 7:27 – Personalized Vaccine Costs, Manufacturing and Moderna’s Growth Outlook
"These corporations have learned how to play the medical-scientific establishment like a Stradivarius," Johns Hopkins cardiology operations chief says after Moderna share price spikes. Its mRNA flu vaccine trial data are still hidden.
Personalized vaccines could be around the corner thanks to decades of work by doctors like Michelle Wu. Her story and details on the new breakthrough on tonight's 11th Hour with Ali Velshi.
Moderna and Merck announced this week that an experimental vaccine for melanoma patients showed positive initial results. Dr. Mahsa Tehrani joins “Elizabeth Vargas Reports” to explain the mRNA technology behind the potential breakthrough. #Health #Cancer #mRNA Anchor Elizabeth Vargas delivers the biggest stories, without bias or opinion. Watch "Elizabeth Vargas Reports" every weeknight at 7p/6C on NewsNation. #VargasReports NewsNation is your source for fact-based, unbiased news for all Americans.
Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial. Why it matters: The results come at a pivotal moment for Moderna and mRNA research, after Trump administration health officials cut federal funding for new vaccines and asserted the technology poses more risks than rewards. - The customized therapy, which could see a commercial launch next year, could also be adapted for other cancers of the kidney, bladder and pancreas. The big picture: The results could lead to a remarkable turnaround for Moderna, whose market value plummeted more than 90% after demand for its COVID vaccine declined…
Moderna and Merck’s mRNA cancer vaccine showed positive results in a late-stage melanoma trial. The vaccine could be available as soon as next year if regulators approve it. Moderna shares surged as much as 160% following the results. Moderna developed the vaccine with Merck and tested it together with Keytruda, a common immunotherapy treatment for melanoma. This is the first successful late-stage trial for an mRNA cancer vaccine. The vaccine works by training a patient’s immune system to recognize and attack specific mutations in cancer cells. It is also the first study to show that adding another treatment to Keytruda worked better than Keytruda alone. Similar vaccines are being studied for lung, breast and pancreatic cancers.…
